In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Eton Pharmaceuticals (ETON – Research Report), with a price target of $33.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors including successful product relaunches and promising future prospects. Eton Pharmaceuticals has exceeded expectations with the relaunch of two acquired products, Increlex and GALZIN, which have shown positive patient adoption and market penetration.
The company is also poised for growth with the anticipated FDA approval and launch of ET-400, an oral hydrocortisone formulation, expected to contribute significantly to revenue in the coming years. Additionally, Eton’s strategic plans to expand the eligible patient population for Increlex and develop an extended-release formulation of zinc, ET-700, further support the potential for increased market share and revenue growth. These factors collectively underpin Ramakanth’s confidence in Eton Pharmaceuticals’ future performance.